McNamara Megan A, George Daniel J
Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA.
Duke University Medical Center, 1 Trent Drive, Morris Building Rm #25169, Box 3841, Durham, NC, 27710, USA.
BMC Cancer. 2015 May 7;15:371. doi: 10.1186/s12885-015-1390-y.
Radium-223 has been shown to improve overall survival in men with metastatic castration-resistant prostate cancer with symptomatic bone metastases. The bone scan response to radium-223 has only been described in one single center trial of 14 patients, none of whom achieved the outstanding bone scan response presented in the current case.
In this case report, we describe a 75 year-old white man with extensively pre-treated metastatic castration-resistant prostate cancer and symptomatic bone metastases who experienced a flare in pain and prostate-specific antigen, followed by dramatic clinical (pain), biochemical (prostate-specific antigen), and imaging (bone scan) response.
The flare phenomena and bone scan response we observed have not previously been described with radium-223. This case suggests that the degree and duration of bone scan response may be predictive of overall survival benefit.
镭-223已被证明可改善有症状性骨转移的转移性去势抵抗性前列腺癌男性患者的总生存期。对镭-223的骨扫描反应仅在一项纳入14例患者的单中心试验中有所描述，这些患者均未出现本病例中所呈现的显著骨扫描反应。
在本病例报告中，我们描述了一名75岁的白人男性，患有广泛预处理的转移性去势抵抗性前列腺癌并有症状性骨转移，其经历了疼痛和前列腺特异性抗原的突发，随后出现了显著的临床（疼痛）、生化（前列腺特异性抗原）和影像学（骨扫描）反应。
我们观察到的突发现象和骨扫描反应此前尚未见镭-223相关报道。本病例提示骨扫描反应的程度和持续时间可能预示着总生存期获益。
